Estabrook Capital Management Amgen Inc Transaction History

Estabrook Capital Management

  • $671 Billion
  • Q3 2024

A detailed history of Estabrook Capital Management transactions in Amgen Inc stock. As of the latest transaction made, Estabrook Capital Management holds 20,415 shares of AMGN stock, worth $5.35 Million. This represents 0.98% of its overall portfolio holdings.

Number of Shares
20,415
Previous 20,732 1.53%
Holding current value
$5.35 Million
Previous $6.48 Billion 1.55%
% of portfolio
0.98%
Previous 1.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$309.38 - $337.38 $98,073 - $106,949
-317 Reduced 1.53%
20,415 $6.58 Billion
Q2 2024

Aug 13, 2024
SELL
$262.75 - $319.31 $84,605 - $102,817
-322 Reduced 1.53%
20,732 $6.48 Billion
Q1 2024

May 14, 2024
SELL
$268.87 - $324.56 $92,491 - $111,648
-344 Reduced 1.61%
21,054 $5.99 Billion
Q4 2023

Feb 13, 2024
SELL
$255.7 - $288.46 $43,980 - $49,615
-172 Reduced 0.8%
21,398 $6.16 Billion
Q3 2023

Nov 13, 2023
SELL
$218.65 - $271.46 $14,649 - $18,187
-67 Reduced 0.31%
21,570 $5.8 Billion
Q2 2023

Aug 11, 2023
SELL
$214.27 - $253.37 $28,069 - $33,191
-131 Reduced 0.6%
21,637 $4.8 Billion
Q1 2023

May 12, 2023
SELL
$225.79 - $275.2 $33,642 - $41,004
-149 Reduced 0.68%
21,768 $5.26 Billion
Q4 2022

Feb 13, 2023
SELL
$229.03 - $291.01 $239,336 - $304,105
-1,045 Reduced 4.55%
21,917 $5.76 Billion
Q3 2022

Nov 14, 2022
SELL
$224.46 - $253.15 $8,978 - $10,126
-40 Reduced 0.17%
22,962 $5.18 Billion
Q2 2022

Aug 15, 2022
SELL
$230.71 - $256.74 $123,660 - $137,612
-536 Reduced 2.28%
23,002 $5.6 Million
Q1 2022

May 13, 2022
SELL
$219.27 - $242.57 $56,352 - $62,340
-257 Reduced 1.08%
23,538 $5.69 Million
Q4 2021

Feb 11, 2022
SELL
$198.88 - $227.6 $88,103 - $100,826
-443 Reduced 1.83%
23,795 $5.35 Million
Q3 2021

Nov 15, 2021
SELL
$212.27 - $248.7 $113,776 - $133,303
-536 Reduced 2.16%
24,238 $5.15 Million
Q2 2021

Aug 13, 2021
SELL
$233.58 - $259.14 $186,163 - $206,534
-797 Reduced 3.12%
24,774 $6.04 Million
Q1 2021

May 14, 2021
SELL
$221.91 - $258.6 $24,188 - $28,187
-109 Reduced 0.42%
25,571 $6.36 Million
Q4 2020

Feb 12, 2021
SELL
$216.38 - $257.67 $9,304 - $11,079
-43 Reduced 0.17%
25,680 $5.9 Million
Q3 2020

Nov 13, 2020
SELL
$234.65 - $260.95 $166,366 - $185,013
-709 Reduced 2.68%
25,723 $6.54 Million
Q2 2020

Aug 13, 2020
SELL
$197.81 - $242.74 $359,816 - $441,544
-1,819 Reduced 6.44%
26,432 $6.23 Million
Q1 2020

May 14, 2020
SELL
$182.24 - $241.7 $455,417 - $604,008
-2,499 Reduced 8.13%
28,251 $5.73 Million
Q4 2019

Feb 13, 2020
SELL
$189.21 - $243.2 $268,867 - $345,587
-1,421 Reduced 4.42%
30,750 $7.41 Million
Q3 2019

Nov 13, 2019
SELL
$174.11 - $208.62 $161,574 - $193,599
-928 Reduced 2.8%
32,171 $6.23 Million
Q2 2019

Aug 13, 2019
SELL
$166.7 - $195.41 $96,352 - $112,946
-578 Reduced 1.72%
33,099 $0
Q1 2019

May 13, 2019
BUY
$180.87 - $203.88 $82,114 - $92,561
454 Added 1.37%
33,677 $0
Q4 2018

Feb 14, 2019
SELL
$178.4 - $208.25 $467,408 - $545,615
-2,620 Reduced 7.31%
33,223 $6.47 Million
Q3 2018

Nov 13, 2018
SELL
$185.29 - $208.89 $157,125 - $177,138
-848 Reduced 2.31%
35,843 $0
Q2 2018

Aug 14, 2018
SELL
$166.05 - $186.51 $606,248 - $680,948
-3,651 Reduced 9.05%
36,691 $0
Q1 2018

May 14, 2018
BUY
$169.43 - $198.0 $7,963 - $9,306
47 Added 0.12%
40,342 $0
Q4 2017

Feb 12, 2018
SELL
$168.79 - $188.59 $16,879 - $18,859
-100 Reduced 0.25%
40,295 $0
Q3 2017

Nov 09, 2017
BUY
$167.29 - $191.0 $6.76 Million - $7.72 Million
40,395
40,395 $0

Others Institutions Holding AMGN

# of Institutions
3,119
Shares Held
407M
Call Options Held
7.56M
Put Options Held
7.2M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $140B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Estabrook Capital Management Portfolio

Follow Estabrook Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Estabrook Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Estabrook Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email